WAMD
Clinical trials for WAMD explained in plain language.
Never miss a new study
Get alerted when new WAMD trials appear
Sign up with your email to follow new studies for WAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye drug could cut injection burden for wet AMD patients
Disease control OngoingThis phase 3 study tests a new drug, EYP-1901, against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 400 adults with the condition will receive either EYP-1901 or aflibercept to see if the new drug can maintain …
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 09:57 UTC
-
New eye drug could mean fewer shots for wet AMD patients
Disease control OngoingThis phase 3 study tests EYP-1901, a new long-acting eye injection, against the standard treatment aflibercept in 400 people with wet age-related macular degeneration (AMD). The goal is to see if EYP-1901 can maintain or improve vision while reducing the number of injections need…
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: WAMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC